AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
Breakthrough Therapy Designation is intended to expedite development and review of investigational medicines.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AbbVie (ABBV) received two FDA Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A) in colorectal and non-small cell lung cancers.
The colorectal cancer designation covers combination treatment with bevacizumab for adults with refractory, metastatic disease previously treated with fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF antibody and, if indicated, an anti-EGFR antibody. The lung cancer designation covers treatment with Temab-A alone for adults with locally advanced or metastatic, EGFR wild-type, c-Met protein-expressing, non-squamous disease after platinum-based chemotherapy and anti-PD-(L)1 antibody therapy.
Both designations were primarily based on the first-in-human M21-404 study. Temab-A has not been approved by global regulatory authorities. Its development program includes Phase 3 and Phase 2/3 studies evaluating treatment alone and in combinations.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFDA Breakthrough Therapy Designation granted for Temab-A with bevacizumab in previously treated adults with refractory, metastatic colorectal cancer.
- Moderate pointFDA Breakthrough Therapy Designation granted for Temab-A alone in previously treated adults with locally advanced or metastatic EGFR wild-type, c-Met-expressing, non-squamous lung cancer.
- Minor pointPhase 3 and Phase 2/3 studies are evaluating Temab-A alone and with other therapies across treatment settings.
Negative
- None.
News Explained
The two designations put Temab-A in an FDA program intended to expedite development and review when clinical evidence may show substantial improvement over existing therapies on a clinically significant endpoint.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
- These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the strength of AbbVie's ADC portfolio, which now includes four BTDs
Temab-A has received two BTDs: one in combination with bevacizumab for adults with refractory, metastatic CRC who have been previously treated with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody (mAb), and if indicated, anti-EGFR mAb therapy. The second designation is for Temab-A as a monotherapy for adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous NSCLC who have previously received treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy. These designations were primarily based on results from the first-in-human study M21-404 (NCT05029882).
"These Breakthrough Therapy Designations reflect the growing clinical evidence supporting c-Met as a meaningful therapeutic target across multiple solid tumors," said Eleni Lagkadinou, M.D., Ph.D., vice president, oncology early development, AbbVie. "As one of the most advanced assets in our next-generation ADC portfolio, Temab-A has demonstrated potential across multiple tumor types, both as a monotherapy and in combinations. We believe these designations further support our strategy of advancing biomarker-driven therapies and underscore our commitment to developing transformative medicines for patients with difficult-to-treat cancers."
Colorectal and lung cancer together affect more than four million people worldwide each year and remain among the leading causes of cancer-related mortality.1,2 Despite advances in treatment, many patients with CRC and advanced NSCLC continue to experience disease progression, underscoring the need for new therapeutic approaches. The FDA's BTD program is intended to expedite the development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
Temab-A is an investigational asset and has not been approved for use by global regulatory authorities.
About Telisotuzumab Adizutecan (Temab-A)
Telisotuzumab adizutecan (Temab-A) is a next-generation, c-Met protein-targeting antibody-drug conjugate (ADC) with a topoisomerase 1 inhibitor (Top1i) payload being investigated in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). The c-Met protein (also known as MET protein), with increased expression in many solid tumors, may contribute to disease progression and treatment resistance, reinforcing its potential as a promising therapeutic target.
Developed using AbbVie's adizutecan platform, Temab-A combines a validated, humanized bivalent IgG1 monoclonal antibody that binds with high affinity to the c-Met protein with the Top1i payload through a cleavable valine-alanine linker and stable bromoacetamide attachment. This design is intended to support targeted delivery while minimizing systemic payload release.
In addition to CRC and NSCLC, Temab-A is being evaluated across other multiple advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), gastroesophageal adenocarcinoma (GEA), pancreatic ductal adenocarcinoma (PDAC), and ovarian cancer (OC). The clinical development program includes multiple Phase 3 and Phase 2/3 studies evaluating Temab-A as both a monotherapy and in combination with other therapies across a range of treatment settings. Additional information about ongoing Temab-A clinical trials can be found on clinicaltrials.gov.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
|
Global Media: Mabel Martinez mabel.martinez@abbvie.com
andrea.yeakel@abbvie.com |
Investors: Liz Shea liz.shea@abbvie.com |
|
|
|
|
|
1 International Agency for Research on Cancer. Lung Cancer Awareness Month 2024. https://www.iarc.who.int/featured-news/lung-cancer-awareness-month-2024/. Accessed October 2026. |
||
|
2 World Health Organization. Colorectal cancer. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer. Accessed October 2026. |
||
View original content:https://www.prnewswire.com/news-releases/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-the-us-fda-for-crc-and-nsclc-302900512.html
SOURCE AbbVie
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which colorectal cancer patients does AbbVie's Temab-A Breakthrough Therapy Designation cover?
The designation covers Temab-A with bevacizumab for adults with refractory, metastatic colorectal cancer previously treated with fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and, if indicated, an anti-EGFR monoclonal antibody.
Which lung cancer patients does AbbVie's Temab-A Breakthrough Therapy Designation cover?
The designation covers Temab-A alone for adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous non-small cell lung cancer who previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy.
What does FDA Breakthrough Therapy Designation mean for AbbVie's Temab-A?
The program is intended to expedite development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Temab-A remains investigational and has not been approved for use by global regulatory authorities.